Todd Chappell
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2024
Profil
Todd Chappell's former jobs include being the Chief Executive Officer at Crystalline Medical, Inc., Rasio Therapeutics, Inc., and Perceptive Navigation LLC.
He also held positions as the Executive Director-New Products at CombinatoRx, Inc. and Vice President-Operations at TetraLogic Research & Development Corp.
Additionally, he worked as the Vice President-Operations at Shape Pharmaceuticals, Inc. .
Mr. Chappell's education history includes an undergraduate degree from the University of California, Los Angeles and an MBA from the Questrom School of Business.
Mr. Chappell's current jobs are as a Consultant at Biohealth Innovation, Inc. and as the Chief Operating Officer at Korro Bio, Inc.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
-.--% | 03.11.2023 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Todd Chappell
Unternehmen | Position | Beginn |
---|---|---|
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Corporate Officer/Principal | 20.01.2014 |
Ehemalige bekannte Positionen von Todd Chappell
Unternehmen | Position | Ende |
---|---|---|
Rasio Therapeutics, Inc. | Vorstandsvorsitzender | 01.03.2021 |
Crystalline Medical, Inc.
Crystalline Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Crystalline Medical, Inc. develops solutions for the rapidly growing image-guided surgery market. Its technology provides for a forward-viewing, image-guided interventional probe that seeks to significantly improve both the safety and efficacy of millions of procedures per year in the areas of interventional radiology, cardiology, interventional oncology, pulmonology, and urology. The company was founded by Theodore P. Abraham in 2012 and is headquartered in Baltimore, MD. | Vorstandsvorsitzender | - |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Corporate Officer/Principal | - |
Ausbildung von Todd Chappell
University of California, Los Angeles | Undergraduate Degree |
Questrom School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
TetraLogic Research & Development Corp.
TetraLogic Research & Development Corp. BiotechnologyHealth Technology TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Finance |
Crystalline Medical, Inc.
Crystalline Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Crystalline Medical, Inc. develops solutions for the rapidly growing image-guided surgery market. Its technology provides for a forward-viewing, image-guided interventional probe that seeks to significantly improve both the safety and efficacy of millions of procedures per year in the areas of interventional radiology, cardiology, interventional oncology, pulmonology, and urology. The company was founded by Theodore P. Abraham in 2012 and is headquartered in Baltimore, MD. | Electronic Technology |
Rasio Therapeutics, Inc. |